Latest Avecho Biotechnology (ASX:AVE) News

One stock nearly doubled, another jumped more than 40%, and a finance heavyweight stayed elevated after a merger shock. In resources, the winners were mostly tied to “what was bought” or “what was funded”, while the laggards were often the ones where early optimism quickly turned into selling.

Avecho and Chimeric both surged as traders chased near-term trial and funding catalysts, while Island Pharmaceuticals extended gains on a US biodefence partnership. Elsewhere, distribution and reimbursement wins supported smaller medtech names, and a cannabis merger plan kept Little Green Pharma in focus ahead of April’s vote.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Small caps stole the week, led by a big funding deal in gold and two revenue breakouts. Meanwhile, some well-known names slid after profit updates failed to calm nerves on costs and outlooks.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Avecho Biotechnology is close to completing recruitment for the interim analysis cohort of its pivotal Phase III trial testing a CBD capsule for insomnia, with results expected in the first half of 2026.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.